{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","spread":"95.4","value":"2870"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"title":"Encorafenib: Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"84.2","value":"582"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"title":"LHY746: Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"45.8","value":"2970"},{"groupId":"OG001","spread":"59.8","value":"2320"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Encorafenib: Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"68.8","value":"864"},{"groupId":"OG001","spread":"82.3","value":"873"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"LHY746: Cycle 1 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"description":"Cmax was observed directly from data. LHY746 is a metabolite of Encorafenib.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received encorafenib 300 milligrams (mg) once daily (QD) orally (received after Cycle 1 Day 3) and cetuximab 500 mg per square meters (mg/m\\^2) intravenous (IV) infusion for 120 minutes once every 2 weeks (Q2W) along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and irinotecan 180 mg/m\\^2 as IV infusion for 90 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG000","title":"SLI: Cohort 1 [EC + FOLFIRI]"},{"description":"Participants received encorafenib 300 mg QD orally and cetuximab 500 mg/m\\^2 IV infusion for 120 minutes Q2W along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and oxaliplatin 85 mg/m\\^2 IV infusion for 120 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG001","title":"SLI: Cohort 2 [EC + mFOLFOX6]"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) parameter analysis set: all enrolled participants treated who had sufficient information to estimate at least 1 of PK parameters of interest and had no major protocol deviations affecting PK assessment. Overall Number of Participants Analyzed: participants evaluable for the outcome measure and Number Analyzed: participants evaluable at specified timepoints. Cohort 1 participants did not receive encorafenib until Cycle 1 Day 3, so there was no analysis done at Cycle 1 Day 1.","reportingStatus":"POSTED","timeFrame":"Cohort 1: Pre-dose (0 hour [hr]), 0.75, 1.5, 2.5, 3.5, 5.5, 7.5, and 48 hrs post-dose on Day 15 of Cycle 1; Cohort 2: Pre-dose (0 hr), 1, 2, 3, 4, 6, 8, and 48 hrs post-dose on Days 1 and 15 of Cycle 1","title":"SLI: Maximum Plasma Concentration (Cmax) of Encorafenib and Its Metabolite LHY746","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter"}